We are well-versed in the legal and regulatory requirements for listing, de-listing and other transactional and corporate actions on the Mainboard and Catalist Board of the Singapore Exchange.

We help our clients meet the challenges of raising funds through various equity and debt capital market transactions. We have experience with initial public offerings (IPOs) and secondary fund-raising, including rights issues and share placements, and debt securities such as convertible notes and warrants.

Recent notable transactions we have undertaken in this area:

Recent notable transactions we have undertaken in this area:

• Advised PrimePartners Corporate Finance Pte. Ltd., the Sponsor, Issue Manager, Underwriter and Co-Placement Agent, and CGS International Securities Singapore Pte. Ltd., the Co-placement Agent, in the S$16.25 million Catalist IPO, by way of a placement of 63,000,000 ordinary shares and public offer of 2,000,000 ordinary shares in the capital of Toku Ltd., a Singapore-based AI-powered end-to-end platform that provides enterprises with seamless and secure customer experiences, completed on 22 January 2026, 2026’s first Catalist listing.
• Advised SGX Catalist-listed Quantum Healthcare Limited on its S$3,000,000 private placement involving an allotment and issuance of 2,727,272,800 new ordinary shares at the placement price of $0.0011 per placement share to two placees procured by the company, completed on 28 November 2025.
• Advised SGX Catalist-listed DISA Limited on its S$3.15 million non-renounceable rights cum warrants issue, completed on 20 June 2025. Advising SGX Catalist-listed DISA Limited on its S$3.15 million (up to S$49.6 million on valid exercise of all warrants) proposed non-renounceable non-underwritten rights cum warrants issue of up to 4,510,123,361 new ordinary shares at an issue price of S$0.001 per share, on the basis of two (2) rights shares for every five (5) existing ordinary shares, and with up to 4,510,123,361 free detachable and transferable warrants, each warrant carrying the right to subscribe for one (1) new ordinary share (“Warrant Share”) at an exercise price of S$0.005 and S$0.010 for each Warrant Share, depending on the exercise period of such warrants, on the basis of one (1) warrant for every one (1) rights share subscribed.
• Acted as Singapore legal advisers to Swift Energy Technology Berhad on its RM84.07 million initial public offering of 250,200,000 new ordinary shares and offer for sale of 50,040,000 existing vendor shares, at the issue price of RM0.28 per share, and listing on the Ace Market of Bursa Securities, Malaysia, completed on 8 January 2025, the first Bursa listing of 2025.
• Advised SGX Catalist-listed GS Holdings Limited on its S$8.40 million renounceable non-underwritten rights issue of up to 570,888,708 new ordinary shares at an issue price of S$0.015 per share, on the basis of two (2) rights shares for every one (1) existing ordinary share, completed on 8 October 2024.
• Advised SGX Catalist-listed Quantum Healthcare Limited on its (i) S$800,000 private placement involving an allotment and issuance of 400,000,000 new ordinary shares at the placement price of $0.002 per placement share to two placees procured by the company, (ii) S300,000 settlement shares issuance involving an allotment and issuance of 150,000,000 new ordinary shares at the settlement price of $0.002 per settlement share to a creditor of the company, both completed on 15 February 2024.